Terminated PHASE3 INTERVENTIONAL NCT00512538

Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

A Randomized, Open-Label, Multi-Center Study to Compare the Safety and Efficacy of Apligraf Versus Standard Therapy (i.e., Saline Moistened Dressing Regimen) in the Treatment of Diabetic (Primarily Neuropathic) Foot Ulcers

Sponsor: Organogenesis

Conditions Diabetic Foot

Interventions Bi-layered cell therapy (Apligraf)

Updated 5 times since 2017 Last updated: Aug 3, 2007 Started: Oct 31, 2000 Completion: Sep 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Interruption of business relations between Study Sponsor and Device Manufacturer

Other terminated trials from Organogenesis

See all terminations from Organogenesis

Other Diabetic Foot trials with similar outcome

Browse all Diabetic Foot trials

This PHASE3 trial investigates Diabetic Foot and is currently terminated or withdrawn. Organogenesis leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Oct 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organogenesis

Data source: Organogenesis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.